FDA's Magic Voucher: Kid Cancer Cure Fast-Tracks Adult Blockbuster Drug
Published Date: 12/19/2025
Notice
Summary
The FDA just gave the green light to KEYTRUDA QLEX, a new medicine for rare pediatric diseases, using a special priority review voucher. This means faster approval for important treatments that kids with rare diseases really need. The approval happened on September 19, 2025, and it shows the FDA’s commitment to speeding up life-saving drugs without extra cost to patients.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Approves KEYTRUDA QLEX for Kids
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) was approved by the FDA on September 19, 2025. The approval was issued under the Rare Pediatric Disease Priority Review Voucher program (section 529 of the FD&C Act), and the FDA determined the product met the voucher redemption criteria.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in